Antiphospholipid Syndrome (APS) and Livedoid Vasculopathy (LV)

By

 Overview

Antiphospholipid Syndrome (APS) is a systemic autoimmune condition characterized by an increased tendency for blood clot formation (thrombosis). It is often associated with Systemic Lupus Erythematosus and may occur as a secondary condition in lupus patients. Although APS is not formally classified as a systemic vasculitis, it is best described as a thrombo-inflammatory disorder. Its hallmark is non-inflammatory vascular injury caused by clotting, but it can sometimes mimic or overlap with vasculitic diseases.

Livedoid Vasculopathy (LV), on the other hand, is a rare, chronic, and painful thrombo-occlusive disease that primarily affects the small blood vessels of the skin, especially in the lower legs. Despite its name, LV is not a true inflammatory vasculitis but rather a disorder driven by microvascular thrombosis.

APS and Vasculitis: Overlap and Distinction

A key challenge in clinical practice is distinguishing APS from true vasculitis:

  • Different mechanisms: APS is defined by thrombosis (clotting), whereas vasculitis involves inflammation of blood vessel walls.
  • Clinical overlap: APS can produce symptoms similar to vasculitis, including skin changes, neurological events (e.g., stroke), and organ ischemia.
  • Coexistence: APS may occur alongside primary vasculitides or autoimmune diseases such as lupus.
  • Atypical cases: Rare forms, such as catastrophic APS, may involve inflammatory features that resemble true vasculitis.

Because treatment differs significantly—anticoagulation for APS versus immunosuppression for vasculitis—accurate diagnosis is critical. In unclear cases, a tissue biopsy is often required to determine whether vessel damage is due to clotting or inflammation.

Livedoid Vasculopathy (LV)

Livedoid vasculopathy is a thrombotic disorder affecting the dermal capillaries. The underlying issue is hypercoagulability, meaning the blood has an increased tendency to clot. These clots block small vessels, reduce oxygen supply, and lead to tissue damage.

Key Clinical Features

  • Livedo racemosa: A persistent, mottled, purplish, net-like discoloration of the skin that does not fade with warming
  • Painful ulcers: Small, extremely painful ulcers, typically on the ankles and feet
  • Atrophie blanche: White, porcelain-like scars that form as ulcers heal, often surrounded by small dilated blood vessels (telangiectasia)

Pathophysiology

The disease is driven by fibrin clot formation within superficial vessels. This occlusion leads to ischemia (lack of oxygen), causing skin breakdown and chronic pain.

Associated Conditions

LV may be:

  • Primary (idiopathic), with no identifiable cause
  • Secondary, associated with conditions such as:
    • Antiphospholipid syndrome
    • Protein C or protein S deficiency
    • Connective tissue diseases

Retinal Involvement and Systemic Disease

Although LV is usually limited to the skin, similar thrombotic processes can rarely affect other vascular beds, including the retina. This is most often seen in systemic conditions such as Sneddon's syndrome, which combines livedo racemosa with cerebrovascular events like stroke.

Mechanism

The same hypercoagulable state responsible for skin findings can lead to clot formation in retinal vessels.

Clinical Presentation

One of the most severe complications is:

  • Central Retinal Artery Occlusion (CRAO): Sudden, painless loss of vision in one eye, often described as a “stroke of the eye”

Clinical Significance

Retinal involvement suggests systemic disease rather than isolated LV. It requires urgent evaluation by ophthalmology and rheumatology, as it may indicate APS or a broader vascular syndrome.

Comparison: Skin vs. Retinal Involvement

Feature

Livedoid Vasculopathy

Retinal Involvement (Systemic Disease)

Location

Skin (lower legs)

Retina (eye)

Pain

Severe, chronic pain

Usually painless

Mechanism

Thrombotic occlusion

Thrombotic occlusion

Outcome

Ulcers, atrophie blanche

Vision loss (e.g., CRAO)



Management and Treatment



Livedoid Vasculopathy

Treatment focuses on improving blood flow and preventing clot formation:

  • Antiplatelet agents (e.g., aspirin)
  • Anticoagulants (e.g., heparin, rivaroxaban)
  • In selected cases, intravenous immunoglobulin (IVIG)



    • APS and Systemic Involvement



    • Long-term anticoagulation is the cornerstone of APS treatment
    • Management of underlying autoimmune disease (if present)

    Retinal Involvement

    • Medical emergency requiring immediate ophthalmologic care
    • Systemic anticoagulation and evaluation for underlying disorders

    Conclusion

    APS and livedoid vasculopathy are closely related through their shared mechanism of abnormal clotting, yet they remain distinct from true inflammatory vasculitis. Both conditions can mimic vasculitic diseases, leading to diagnostic challenges. Recognizing the difference between thrombotic and inflammatory vascular disease is essential, as treatment strategies differ fundamentally. While LV is typically confined to the skin, the presence of retinal or neurological involvement should raise concern for systemic disease, prompting urgent and comprehensive evaluation.

    References:

    Livedoid Vasculopathy 
    https://www.sciencedirect.com/topics/medicine-and-dentistry/livedoid-vasculopathy

    Successful Treatment of Central Nervous System Vasculitis Associated with Antiphospholipid Syndrome 
    https://www.j-nn.org/journal/view.php?number=164

    Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review https://pmc.ncbi.nlm.nih.gov/articles/PMC11066154/

    Acute Central Retinal Artery Occlusion Associated with Livedoid Vasculopathy: A Variant of Sneddon's Syndrome https://pmc.ncbi.nlm.nih.gov/articles/PMC3782585/

    Antiphospholipid Syndrome and Endothelial Injury: Unraveling the Links with Complement Hyperactivation and Thrombotic Microangiopathy in Severe COVID-19 
    https://swaresearch.blogspot.com/2025/02/antiphospholipid-syndrome-and.html

    © 2000-2030 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a five-year copyright. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9 

    Comments

    Post a Comment

    Popular posts from this blog

    Schnitzler Syndrome: A Rare Autoinflammatory Disorder

    By
    Schnitzler syndrome is a rare, chronic autoinflammatory disease characterized by chronic urticaria (hives), recurrent fever, joint pain, and monoclonal gammopathy (abnormal proteins in the blood). First described by Dr. Liliane Schnitzler in 1972 , this condition is often misdiagnosed, leading to years of untreated symptoms before a correct diagnosis is made. The case report, " A 58-Year-Old Woman With Urticaria, Fever, and Joint Pain " , describes a case that closely aligns with my own experience with this challenging disorder. Key Features of Schnitzler Syndrome Schnitzler syndrome presents with a characteristic set of symptoms, though not all patients experience them in the same way: Chronic Urticaria (Hives) – Persistent, non-itchy or mildly itchy red patches that do not respond to antihistamines. Monoclonal Gammopathy (IgM or IgG type) – Abnormal monoclonal immunoglobulin detected in the blood (most commonly IgM ). Recurrent Fever – Unexplained fever episodes, often...
    Read more

    Acute Flaccid Myelitis (AFM): Understanding the “Polio-like” Illness Affecting the Spinal Cord

    By
    Acute flaccid myelitis (AFM) is a rare but serious neurological disorder that primarily affects children and results in sudden weakness or paralysis in the limbs. Often referred to as a “polio-like” illness, AFM has drawn growing attention over the past decade due to its similarities with poliomyelitis and its seasonal spikes in reported cases. While AFM remains uncommon, its potential severity—and the uncertainty surrounding its causes—make it an important condition for clinicians, parents, and public health officials to understand. What Is Acute Flaccid Myelitis? AFM is a condition that affects the gray matter of the spinal cord , where it damages motor neurons responsible for muscle movement. This leads to acute, flaccid paralysis , meaning muscles become limp and weak, often without warning. The condition can progress rapidly, and in some cases, the weakness can become long-lasting or even permanent. Although its symptoms resemble those of poliovirus infection, AFM is not cau...
    Read more

    Very Long-Chain Fatty Acids (VLCFAs) X-ALD and Spinal Muscular Atrophy (SMA): Exploring the Connection

    By
    Image
    Introduction: White Brain Matter, VLCFAs, and X-ALD X-linked Adrenoleukodystrophy (X-ALD) is a rare inherited metabolic disorder and a major cause of progressive neurodegeneration in children—sometimes referred to as “childhood dementia.” Across related conditions, prevalence can range from approximately 1 in 2,000 to 1 in 500,000 newborns. Among its forms, childhood cerebral X-ALD is the most severe, marked by rapid inflammatory demyelination in the brain and often fatal outcomes if not treated early. At the core of X-ALD is a disruption in the metabolism of Very Long-Chain Fatty Acids (VLCFAs). Normally, these fatty acids are broken down in peroxisomes—specialized structures within cells that help maintain metabolic balance. In X-ALD, a mutation in the ABCD1 gene impairs this function, causing VLCFAs to accumulate, particularly in the white matter of the brain, spinal cord, and adrenal glands. This accumulation leads to demyelination, adrenal insufficiency (Addison’s disease), an...
    Read more

    Dysferlin Protein: Key Roles, Genetic Locations

    By
    Image
    The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
    Read more

    Toxic Skin Condition Post-mRNA COVID-19 Vaccination

    By
    Image
    Important update: My experiences have now been formally verified following several years of dismissal. Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations https://link.springer.com/article/10.1186/s12985-025-03032-x  ----------------------------------------- Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially pres...
    Read more

    Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

    By
    Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
    Read more

    Polio and Post-Polio Syndrome (PPS): Summary and Key Insights

    By
    Image
      In the human body, poliovirus can survive and replicate for varying durations depending on the phase of infection and the individual's immune response: Incubation Period : After entering the body, poliovirus can begin replicating in the throat and intestines within a few hours. The typical incubation period lasts 7 to 10 days (but can range from 3 to 35 days ), during which the virus is actively multiplying. Shedding in Feces : Even after symptoms have resolved or in asymptomatic cases, poliovirus can be excreted in the feces for an extended period. In most individuals, the virus is shed in feces for 4 to 8 weeks after infection. In rare cases, especially in individuals with compromised immune systems, the virus may persist in the gut and be shed for months or even years (a condition called chronic excretion ). Bloodstream : If the virus enters the bloodstream and causes viremia, it may persist there for a few days before being cleared by the immune system or progressing to ...
    Read more

    Cytokine Storm, Mast Cell Activation Syndrome (MCAS), Endothelial Dysfunction and microclots/thrombosis?

    By
    Update: New Research Builds on Previous Findings Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832234?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=040925&adv= Conclusions: This recent cohort study builds upon earlier work by identifying COVID-related cytokine storm (COVID-CS) through common inflammation markers and comparing it with two other cytokine storm (CS) conditions: malignancy-associated hemophagocytic lymphohistiocytosis (MN-HLH) and CAR-T–associated cytokine release syndrome (CAR-T CRS) . Among the three groups, patients treated with CAR-T therapy showed the highest survival rates , in contrast to those with COVID-CS and MN-HLH. Interestingly, the study found that CAR-T CRS and COVID-CS share similar cytokine activation pathways , suggesting a comparable immune response mechanism. In c...
    Read more

    Introduction to Adenosine and Tachycardia

    By
    What is Adenosine? Adenosine is a chemical found in human cells, existing in three forms: adenosine, adenosine monophosphate (AMP), and adenosine triphosphate (ATP). Adenosine is a chemical found in the body that plays many roles, including influencing heart rate and promoting sleep and relaxation. It is also used as a medication to manage certain types of tachycardia, particularly supraventricular tachycardia. Adenosine works by slowing the heart rate through its action on the cardiac tissue. Adenosine production in the body occurs through multiple pathways: Phosphorylation of Adenine: Adenine can be directly phosphorylated to form AMP (adenosine monophosphate), which is then converted to ATP, ADP, and finally adenosine through dephosphorylation reactions. Breakdown of ATP: Adenosine is primarily formed in the body through the breakdown of ATP, which releases energy. ATP can be dephosphorylated stepwise through the action of various enzymes: ATP is first converted to ADP (adeno...
    Read more

    RBC and WBC from the bone marrow to the vascular system

    By
      The image above illustrates the process of hematopoiesis in the bone marrow, depicting how stem cells differentiate into various types of blood cells including red blood cells, white blood cells, and platelets. It shows the progression from pluripotent stem cells through various stages of differentiation, leading to the mature forms of each cell type, with labels for the main stages of cell differentiation. This provides a clear, educational overview of how blood cells are formed from stem cells in the bone marrow. Red blood cells (RBCs) and white blood cells (WBCs) originate from stem cells in the bone marrow through a complex process known as hematopoiesis. Once they are formed, these cells enter the bloodstream to perform their respective functions throughout the body. The process of how these cells move from the bone marrow into the vascular system involves several steps: Hematopoiesis : This is the process by which stem cells in the bone marrow differentiate into vari...
    Read more